TY - JOUR
T1 - Molecular Signaling and Dysfunction of the Human Reactive Enteric Glial Cell Phenotype
T2 - Implications for GI Infection, IBD, POI, Neurological, Motility, and GI Disorders
AU - Liñán-Rico, Andromeda
AU - Turco, Fabio
AU - Ochoa-Cortes, Fernando
AU - Harzman, Alan
AU - Needleman, Bradley J.
AU - Arsenescu, Razvan
AU - Abdel-Rasoul, Mahmoud
AU - Fadda, Paolo
AU - Grants, Iveta
AU - Whitaker, Emmett
AU - Cuomo, Rosario
AU - Christofi, Fievos L.
N1 - Publisher Copyright:
© 2016 Crohn's & Colitis Foundation of America, Inc.
PY - 2016/5/31
Y1 - 2016/5/31
N2 - Background: Clinical observations or animal studies implicate enteric glial cells in motility disorders, irritable bowel syndrome, inflammatory bowel disease, gastrointestinal (GI) infections, postoperative ileus, and slow transit constipation. Mechanisms underlying glial responses to inflammation in human GI tract are not understood. Our goal was to identify the "reactive human enteric glial cell (rhEGC) phenotype" induced by inflammation, and probe its functional relevance. Methods: Human enteric glial cells in culture from 15 GI-surgical specimens were used to study gene expression, Ca 2+, and purinergic signaling by Ca 2+ /fluo-4 imaging and mechanosensitivity. A nanostring panel of 107 genes was designed as a read out of inflammation, transcription, purinergic signaling, vesicular transport protein, channel, antioxidant, and other pathways. A 24-hour treatment with lipopolysaccharide (200 g/mL) and interferon-γ (10 g/mL) was used to induce inflammation and study molecular signaling, flow-dependent Ca 2+ responses from 3 mL/min to 10 mL/min, adenosine triphosphate (ATP) release, and ATP responses. Results: Treatment induced a "rhEGC phenotype" and caused up-regulation in messenger RNA transcripts of 58% of 107 genes analyzed. Regulated genes included inflammatory genes (54%/IP10; IFN-γ; CxCl2; CCL3; CCL2; C3; s100B; IL-1β; IL-2R; TNF-α; IL-4; IL-6; IL-8; IL-10; IL-12A; IL-17A; IL-22; and IL-33), purine-genes (52%/AdoR2A; AdoR2B; P2RY1; P2RY2; P2RY6; P2RX3; P2RX7; AMPD3; ENTPD2; ENTPD3; and NADSYN1), channels (40%/Panx1; CHRNA7; TRPV1; and TRPA1), vesicular transporters (SYT1, SYT2, SNAP25, and SYP), transcription factors (relA/relB, SOCS3, STAT3, GATA-3, and FOXP3), growth factors (IGFBP5 and GMCSF), antioxidant genes (SOD2 and HMOX1), and enzymes (NOS2; TPH2; and CASP3) (P < 0.0001). Treatment disrupted Ca 2+ signaling, ATP, and mechanical/flow-dependent Ca 2+ responses in human enteric glial cells. ATP release increased 5-fold and s100B decreased 33%. Conclusions: The "rhEGC phenotype" is identified by a complex cascade of pro-inflammatory pathways leading to alterations of important molecular and functional signaling pathways (Ca 2+, purinergic, and mechanosensory) that could disrupt GI motility. Inflammation induced a "purinergic switch" from ATP to adenosine diphosphate/adenosine/uridine triphosphate signaling. Findings have implications for GI infection, inflammatory bowel disease, postoperative ileus, motility, and GI disorders.
AB - Background: Clinical observations or animal studies implicate enteric glial cells in motility disorders, irritable bowel syndrome, inflammatory bowel disease, gastrointestinal (GI) infections, postoperative ileus, and slow transit constipation. Mechanisms underlying glial responses to inflammation in human GI tract are not understood. Our goal was to identify the "reactive human enteric glial cell (rhEGC) phenotype" induced by inflammation, and probe its functional relevance. Methods: Human enteric glial cells in culture from 15 GI-surgical specimens were used to study gene expression, Ca 2+, and purinergic signaling by Ca 2+ /fluo-4 imaging and mechanosensitivity. A nanostring panel of 107 genes was designed as a read out of inflammation, transcription, purinergic signaling, vesicular transport protein, channel, antioxidant, and other pathways. A 24-hour treatment with lipopolysaccharide (200 g/mL) and interferon-γ (10 g/mL) was used to induce inflammation and study molecular signaling, flow-dependent Ca 2+ responses from 3 mL/min to 10 mL/min, adenosine triphosphate (ATP) release, and ATP responses. Results: Treatment induced a "rhEGC phenotype" and caused up-regulation in messenger RNA transcripts of 58% of 107 genes analyzed. Regulated genes included inflammatory genes (54%/IP10; IFN-γ; CxCl2; CCL3; CCL2; C3; s100B; IL-1β; IL-2R; TNF-α; IL-4; IL-6; IL-8; IL-10; IL-12A; IL-17A; IL-22; and IL-33), purine-genes (52%/AdoR2A; AdoR2B; P2RY1; P2RY2; P2RY6; P2RX3; P2RX7; AMPD3; ENTPD2; ENTPD3; and NADSYN1), channels (40%/Panx1; CHRNA7; TRPV1; and TRPA1), vesicular transporters (SYT1, SYT2, SNAP25, and SYP), transcription factors (relA/relB, SOCS3, STAT3, GATA-3, and FOXP3), growth factors (IGFBP5 and GMCSF), antioxidant genes (SOD2 and HMOX1), and enzymes (NOS2; TPH2; and CASP3) (P < 0.0001). Treatment disrupted Ca 2+ signaling, ATP, and mechanical/flow-dependent Ca 2+ responses in human enteric glial cells. ATP release increased 5-fold and s100B decreased 33%. Conclusions: The "rhEGC phenotype" is identified by a complex cascade of pro-inflammatory pathways leading to alterations of important molecular and functional signaling pathways (Ca 2+, purinergic, and mechanosensory) that could disrupt GI motility. Inflammation induced a "purinergic switch" from ATP to adenosine diphosphate/adenosine/uridine triphosphate signaling. Findings have implications for GI infection, inflammatory bowel disease, postoperative ileus, motility, and GI disorders.
KW - adenosine
KW - ATP
KW - bacterial lipopolysaccharide
KW - Ca 2 signaling
KW - human enteric glial cells
KW - mechanosensitivity
KW - purinergic signaling
UR - http://www.scopus.com/inward/record.url?scp=84979884714&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84979884714&partnerID=8YFLogxK
U2 - 10.1097/MIB.0000000000000854
DO - 10.1097/MIB.0000000000000854
M3 - Article
C2 - 27416040
AN - SCOPUS:84979884714
SN - 1078-0998
VL - 22
SP - 1812
EP - 1834
JO - Inflammatory bowel diseases
JF - Inflammatory bowel diseases
IS - 8
ER -